Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SL-172154 |
| Trade Name | |
| Synonyms | SL172154|SL 172154|CD172a-Fc-CD40L Chimeric Protein SL-172154 |
| Drug Descriptions |
SL-172154 is a fusion protein that is engineered to target CD47 on tumor cells and CD40 on antigen presenting cells (APCs), which inhibits CD47/SIRPa signaling and potentially results in increased anti-tumor immune response (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C173706 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Azacitidine + SL-172154 | Azacitidine SL-172154 | 0 | 1 |
| Azacitidine + SL-172154 + Venetoclax | Azacitidine SL-172154 Venetoclax | 0 | 1 |
| Mirvetuximab Soravtansine + SL-172154 | Mirvetuximab Soravtansine SL-172154 | 0 | 1 |
| Pegylated liposomal doxorubicin + SL-172154 | Pegylated liposomal doxorubicin SL-172154 | 0 | 1 |
| SL-172154 | SL-172154 | 0 | 3 |
| SL-172154 + Venetoclax | SL-172154 Venetoclax | 0 | 0 |